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Abstract 
Background: CEA, CYFRA21-1 and NSE are tumor markers used for monitoring the response to chemotherapy in 
advanced adenocarcinoma, squamous cell carcinoma and small-cell lung cancer, respectively. Their role in cancer 
immunotherapy needs to be elucidated.
Methods: Patients with advanced non-small cell lung cancer (NSCLC) were treated with nivolumab 3 mg/kg every 
2 weeks within the Italian Nivolumab Expanded Access Program. Blood samples were collected at baseline, at each 
cycle up to cycle 5 and then every two cycles until patient’s withdrawn from the study. All patients underwent a CT-
scan after every 4 cycles of treatment and responses were classified according to RECIST 1.1. The biomarkers serum 
levels were measured with a chemiluminescent microparticle immunoassay for CEA and with an immuno radiometric 
assay for CYFRA21-1 and NSE. The markers values at baseline and after 4 cycles were used to analyze the relationship 
between their variation over baseline and the tumor response, evaluated as disease control rate (DCR: CR + PR + SD), 
and survival (PFS and OS).
Results: A total of 70 patients were evaluable for the analysis. Overall, a disease control was obtained in 24 patients 
(35.8%, 4 PR + 20 SD). After 4 cycles of nivolumab a CEA or CYFRA21-1 reduction ≥ 20% over the baseline was signifi-
cantly associated with DCR (CEA, p = 0.021; CYFRA21-1, p < 0.001), PFS (CEA, p = 0.028; CYFRA21-1, p < 0.001) and OS 
(CEA, p = 0.026; CYFRA21-1, p = 0.019). Multivariate analysis confirmed the ability of CYFRA21-1 reduction ≥ 20% to 
predict DCR (p = 0.002) and PFS (p < 0.001).
Conclusion: The reduction in serum level of CYFRA21-1 or CEA might be a reliable biomarker to predict immuno-
therapy efficacy in NSCLC patients. NSE was not significant for monitoring the efficacy of nivolumab.
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Background
Advanced lung cancer remains the leading cause of 
cancer related deaths worldwide being the treatment 
of disease still challenging [1]. Immunotherapy is a 
standard of treatment in advanced non-small cell lung 
cancer (NSCLC) patients progressing after a first-line 
chemotherapy or as first-line treatment in combination 
with chemotherapy or as single agent in patients with 
high expression of PD-L1. Several agents targeting 
immune checkpoints have been tested with remark-
able results on survival and manageable toxicity [2]. 
Nivolumab (BMS-936558) is a fully human IgG4 pro-
grammed cell death 1 (PD-1) immune checkpoint inhibi-
tor that enhances the immune T cell response by blocking 
the interaction between the PD-1, an inhibitory receptor 
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death ligand 1 (PD-L1) expressed on cancer cells. Two 
randomized Phase III studies have been reported on 
squamous (CheckMate 017) and non-squamous (Check-
Mate 057) NSCLC [3, 4] leading to drug approval by the 
Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) for advanced or metastatic 
NSCLC after prior chemotherapy. This improvement in 
the management of advanced NSCLC has required the 
identification of prognostic and/or predictive biomark-
ers to select the best candidates to immunotherapy and 
to monitor the tumor response [5]. PD-L1 expression has 
been widely explored as a potential marker but its role 
in the clinical setting is still controversial [6]. Serologi-
cal biomarkers such as carcinoembryonic antigen (CEA), 
cytokeratin fragment 19 (CYFRA21-1) and neuron-
specific enolase (NSE), have been mainly investigated 
as prognostic or predictive markers in NSCLC patients 
treated with chemotherapy [7, 8]. CEA is a serum gly-
coprotein and currently is the most widely used marker 
for colorectal, breast and lung cancer. Increased lev-
els of CEA are observed in smokers and in presence of 
non-neoplastic disease [9, 10]. CYFRA21-1 is a fragment 
of cytokeratin 19 that is abundant in the pulmonary tis-
sue. Serum concentrations are particularly elevated in the 
carcinoid tumors and in squamous cell carcinoma of the 
lung where it correlates with the tumor size, lymph node 
status and the stage of disease [11, 12]. As a result, CEA 
and CYFRA21-1 have been identified as useful prognos-
tic factors [7–13], as predictors of efficacy for targeted 
therapy [14, 15] or chemotherapy [8] and as markers of 
postoperative recurrence and metastasis [16–18]. NSE is 
a cytosolic enzyme expressed at high levels in the brain 
and preferentially in neurons and neuroendocrine cells 
[19]. As a specific serum marker of neuronal injury, ele-
vated levels of NSE have been found in cancers of neu-
roendocrine cellular origin, including small-cell lung 
cancer (SCLC) where it correlates with the extent of dis-
ease [20, 21]. For SCLC the NSE has a specificity around 
85% and is useful for prognosis of survival, monitoring of 
treatment and prediction of relapse [16, 21, 22]. Increased 
levels of NSE have also been reported in NSCLC where 
its role as predictive and prognostic marker is still under 
debate. Tiseo et  al. reported a significant correlation 
between higher baseline serum NSE levels and response 
to standard first-line chemotherapy in advanced NSCLC 
whereas did not find a prognostic role [23]. A recent 
meta-analysis including 2389 NSCLC patient has con-
firmed the lack of prognostic significance for NSE [24]. 
In addition, in a recent study Fiala et  al. have showed a 
negative predictive role of high baseline NSE levels in 
NSCLC patients treated with epidermal growth factor 
tyrosine kinase inhibitors (EGFR-TKIs) [25]. The role of 
CEA, CYFRA21-1 and NSE in monitoring the response 
to immunotherapy in NSCLC patients needs to be elu-
cidated. In the present study we tested the hypothesis 
that their variation compared to the baseline may act as 
indicators of treatment efficacy and survival in advanced 
NSCLC patients treated with nivolumab.
Methods
Patient’s enrollment
Between May 2015 and May 2016, 74 consecutive 
patients with advanced NSCLC previously treated with 
at least one line of chemotherapy were prospectively 
enrolled in a single-institutional translational research 
study at the Ospedale Policlinico San Martino in Gen-
ova, Italy, within the Italian Nivolumab Expanded Access 
Program. This study was approved by the Ethics Com-
mittee of Liguria Region (Italy) (P.R.191REG2015) and 
conducted in compliance with the principle of the Dec-
laration of Helsinky; a written informed consent was 
acquired from all patients. All the patients were treated 
with nivolumab at the dose of 3  mg/kg every 2  weeks 
until disease progression, unacceptable toxicity, patient 
refusal, or death. Baseline assessments were done with a 
computed tomography scan (CT scan) of the chest and 
abdomen within 2 weeks before treatment and then after 
4 cycles of treatment. The tumor response was assessed 
according to Response Evaluation Criteria in Solid 
Tumors (RECIST ver 1.1) [26]. Each patient’s response 
was classified into one of the following categories: 
responders, including case of complete response (CR), 
partial response (PR) and stable disease (SD), and non-
responders including cases of disease progression (PD). 
Disease control rate (DCR) was defined as those patients 
who had obtained a CR, a PR or a SD. For patients who 
achieved a PD, an additional assessment was performed 
after 2 further cycles to confirm PD; if PD was confirmed, 
treatment was discontinued.
Specimen collection and tumor marker assays
The tumor markers were determined collecting a 
blood sample before treatment initiation (baseline 
visit), at each cycle up to cycle 5 and then every two 
cycles until patient’s withdrawn from the study. Serum 
levels of CEA were detected using a commercially 
available chemiluminescent microparticle immunoas-
say (Architect CEA Reagent kit, Abbott Diagnostics 
Division) whereas CYFRA21-1 and NSE were detected 
using a commercially available immuno radiometric 
assay (Cytokeratin 19 Fragment IRMA Kit and NSE 
IRMA Kit, Beckman Coulter Inc.) according to the 
manufacturer’s instructions. The reference range 
was 0 to 5 ng/ml for CEA, 0 to 3.3 ng/ml for CYFRA 
21-1, 0 to 13.4  ng/ml for NSE. Hemolyzed samples 
were excluded from the analysis. The markers levels 
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at baseline and after 4 cycles of nivolumab were used 
to analyze the relationship between their variation 
over the baseline and the tumor response, considered 
as disease control rate (DCR), progression free sur-
vival (PFS) and overall survival (OS). On the basis of 
the results from an our previous study in advanced 
NSCLC patients treated with standard first-line chem-
otherapy [8], a post-treatment drop in serum concen-
tration ≥ 20% over baseline was used as cut-off level 
for defining a marker response. In addition, a sub-
analysis of the three markers in the different histologi-
cal types was further investigated.
Statistical analysis
Variables were summarized as median (range) for 
continuous variables and number (%) for categori-
cal variables. Relationships between categorical vari-
ables were examined by means of the Chi square test. 
Patients were categorized according to median age 
(≤ 70 and > 70 years) and histology (adenocarcinoma vs 
squamous cell carcinoma). Non-parametric tests were 
used to check differences between the two groups and 
to compare the markers values at baseline and after 4 
cycles of treatment. Odds Ratios (OR) and the corre-
sponding 95% confidence intervals (95% CI) for a set 
of individual and clinical variables were computed to 
predict therapy response in a multiple logistic analysis. 
Univariate and multivariate analyses were performed 
to evaluate the prognostic impact on PFS and on OS; 
PFS was calculated from the start of nivolumab to the 
date of PD or death or last follow-up; OS was calculated 
from the start of nivolumab to the date of death or last 
follow-up. The Kaplan–Meier method was applied to 
estimate survival probabilities and the log-rank test was 
carried out to assess heterogeneity within each prog-
nostic factor. Cox’s proportional hazards regression 
model was carried out as multivariate analysis to assess 
the prognostic role of the markers adjusted for the pos-
sible confounding effect of all other factors included in 
the same model. All statistical test were two-sided, and 




Seventy out of 74 patients were evaluable for serum 
markers and response assessment after 4 cycles of 
nivolumab (4 patients were excluded from the analysis 
for hemolyzed baseline samples). Three patients stopped 
nivolumab for toxicity before the first CT scan evalu-
ation. The clinicopathological characteristics are sum-
marized in Table 1. The median age was 70 years (range 
44–85) and 69% of patients were male. NSCLC included 
54 adenocarcinomas (77%), 15 squamous cell carcinomas 
(22%) and one case of not otherwise specified (NOS) type 
(1%). The majority of the patients were smokers (87%), 
had metastatic disease (96%) and ECOG PS 0–1 (92%). 
The median number of prior lines of treatment was 2 
(range 1–6). The median value of the serum levels of the 
three markers at baseline (pre-treatment) was 6.6  ng/
ml for CEA (range 0.8–2615), 5  ng/ml for CYFRA21-1 
Table 1 Clinicopathological characteristics
NOS, not otherwise specified; ECOG, Eastern cooperative oncology group; PS, 
performance status; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin 
fragment 19; NSE, neuron-specific enolase
No. of patients (70) %
















Never smoker 9 13
Former smoker 35 50
Smoker 26 37




≥ 4 9 12
CEA (ng/ml) baseline
Median (range) 6.6 (0.80–2615)
Normal (< 5) 30 43
Elevated (≥ 5) 40 57
CYFRA 21-1 (ng/ml) baseline
Median (range) 5.0 (0.2–126.4)
Normal (< 3.3) 25 36
Elevated (≥ 3.3) 45 64
NSE (ng/ml) baseline
Median (range) 7.5 (3.1–46.8)
Normal (< 3.3) 56 80
Elevated (≥ 3.3) 14 20
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(range 0.2–126.4) and 7.5  ng/ml (range 3.1–46.8) for 
NSE. Pre-treatment values over the upper normal limit of 
CEA, CYFRA 21-1 and NSE were detected in 40 (57%), 
45 (64%), and 14 (20%) patients, respectively. At cycle 
2 and cycle 3 data on CEA were available for 59 and 54 
patients, respectively, while data on CYFRA 21-1 were 
available for 57 and 54 patients, respectively. At the same 
time points data on NSE were available for 58 and 50 
patients, respectively.
Correlation between serum markers levels, 
clinic‑pathologic features and tumor response
No significant correlation was found between baseline 
markers serum levels and age or gender. Abnormal base-
line CEA levels were found in current smokers (p = 0.048) 
and in adenocarcinomas (p < 0.001). Abnormal, but not 
significant, baseline CYFRA21-1 levels were found in 
squamous tumors. No association was found between 
baseline NSE levels and patient and cancer characteristics 
(data not shown). On average, patients received 6 cycles 
of nivolumab (range 1–36) and a first CT scan evaluation 
was performed after a median time of 6.9  weeks, cor-
responding to 4 cycles of nivolumab,. Overall, a disease 
control was obtained in 24/67 patients (35.8%, 4 PR and 
20 SD). Age, gender, histology, stage, ECOG PS, smok-
ing habit and baseline serum levels did not correlate with 
response to nivolumab (data not shown). After 4 cycles 
of nivolumab the median CEA and NSE levels remained 
rather stable compared to baseline (5.1 ng/ml and 7.4 ng/
ml, respectively) while the median CYFRA 21-1 levels 
dropped to 2.7 ng/ml. Interestingly, in those patients who 
obtained a DCR we observed a decline of all three serum 
markers with a significant difference between respond-
ers and no-responders (Table  2). Overall, CEA, CYFRA 
21-1 and NSE reduction ≥ 20% occurred in 13/49 (26%), 
17/50 (34%) and 16/44 (36%) patients, respectively, and 
a CEA and CYFRA 21-1 reduction were associated with 
favorable DCR (Table 3). With RECIST, a decrease ≥ 20% 
of CEA was achieved in 43.5% of responders and in 11.5% 
of no-responders (p = 0.021), while a decrease ≥ 20% of 
CYFRA21-1 occurred in 62.5% of responders and in 7.7% 
of no-responders (p < 0.001). Interestingly, we observed 
that a tumor response occurred in 87.5% of patients with 
a CYFRA21-1 reduction ≥ 20% already presents after the 
1st cycle (p = 0.008) and in 80% of patients with a CEA 
reduction ≥ 20% already presents after the 2nd cycle 
(p = 0.033) (data not shown).
Multivariate analysis, including variables for age, gen-
der, CEA and CYFRA reduction ≥ 20%, revealed that 
CYFRA21-1 reduction ≥ 20% was an independent posi-
tive predictor factor for DCR (HR 4.36, 95% CI 1.7 to 
11.3, p = 0.002) (Table  4). Interestingly, we observed 
that the reduction ≥ 20% of the tumor markers was 
already evident at the beginning of the therapy. In par-
ticular, the decrease of at least 20% had already evident 
after the 1th, 2nd and 3rd cycle in 5%, 20%, and 28% of 
patients for CEA, in 15%, 37% and 39% of patients for 
CYFRA21-1 and in 26%, 22%, and 34% of patients for 
NSE, respectively (data not shown). Finally, analyz-
ing the tumor markers on the basis of histotype we 
observed that patients with adenocarcinoma reached a 
DCR when CEA and CYFRA21-1 reduction was ≥ 20%, 
with a significant difference in response compared to the 
patients with marker reduction < 20% (CEA, 77% vs 40%, 
p = 0.043; CYFRA21-1, 92% vs 35%, p = 0.001). Among 
the patients with squamous cell carcinoma, we observed 
a reduction ≥ 20% for CYFRA21-1 and NSE but only a 
CYFRA21-1 reduction resulted in DCR (p = 0.033). In 
both histological types NSE reduction ≥ 20% did not 
show to be significantly associated with DCR (data not 
shown).
Association between CEA, CYFRA 21‑1, NSE and PFS
Overall, median PFS on 67 patients was 1.9 months (95% 
CI 1.7–2.2  months). Age, sex, histology, PS, smoking, 
prior treatment lines and baseline serum marker lev-
els were not associated with PFS. In contrast, a longer 
PFS was observed in patients with normal baseline 
CEA values (2.7  months vs 1.7  months, p = 0.026) and 
with a CEA and CYFRA21-1 reduction ≥ 20% after 4 
cycles of nivolumab (CEA: 7.1 vs 1.9 months, p = 0.028; 
CYFRA21-1: 7.9 vs 1.9 months, p < 0.001). No significant 
association was found between NSE reduction ≥ 20% 
and PFS (4.7 vs 1.9  months, p = 0.300) (Fig.  1). Multi-
variate analysis including terms for gender, age, CEA, 
CYFRA21-1 and NSE reduction ≥ 20% confirmed the 
positive prognostic role only for CYFRA21-1 reduc-
tion ≥ 20% (HR = 0.35, 95% CI 0.20–0.60, p < 0.001) (data 
not shown). Considering histology, a marker’s reduction 
improved PFS in adenocarcinoma patients (CEA,7.1 vs 
Table 2 CEA, CYFRA 21-1 and  NSE variation according 
to response to nivolumab
Median (%) Range (%) p‑value
CEA
No responder + 31 − 79; + 498 0.005
Responder − 9 − 92: + 88
CYFRA21-1
No responder + 72 − 62; + 508 < 0.001
Responder − 37 − 98; + 2220
NSE
No responder + 20 − 64; + 182 0.012
Responder − 14 − 79; + 71
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1.9  months, p = 0.013; CYFRA21-1, 7.9 vs 1.9  months 
p < 0.001; NSE 5.9 vs 1.9  months, p = 0.067), while in 
patients with squamous carcinoma PFS was improved 
only in patients with CYFRA21-1 reduction ≥ 20% (6.1 vs 
1.7 months, p = 0.032).
Association between CEA, CYFRA 21‑1, NSE and OS
For the whole study population, median follow up was 
10.7  months (range 5.0–16.8) for censored patients and 
3.1  months (range 0.1–13.2) for deceased patients. The 
association between clinicopathological characteristics 
and serum markers with OS is shown in Table 5. Median 
survival time was 9.2  months (95% CI 5.3–13.2). Dur-
ing the study period, 40 patients (57.1%) died. In the 
univariate analysis, a statistically significant prognostic 
effect was found for number of prior lines of treatment 
(n = 1, 6.1 months, 95% CI = 3.6–8.5; n ≥ 2, 12.2 months, 
95% CI = 8.2–13.3, p = 0.036) and for response to 
therapy (13.5 months for responders vs 6.4 months for no-
responders, p < 0.001). At baseline, normal markers levels 
were significantly associated with better OS: 12.1 months 
for CEA < 5  ng/ml vs 5.6  months for CEA ≥ 5  ng/ml, 
p = 0.035; 13.2  months for CYFRA21-1 < 3.3  ng/ml vs 
5.6  months for CYFRA21-1 ≥ 3.3  ng/ml, p = 0.005 and 
10.0  months for NSE < 13.4  ng/ml vs 2.2  months for 
NSE ≥ 13.4 ng/ml, p = 0.028.
In addition, also a reduction ≥ 20% of CEA or 
CYFRA21-1 after 4 cycles of nivolumab represented 
a positive prognostic factor (Table  6). In particular, 
Kaplan–Meier survival curves showed that patients with 
CEA or CYFRA21-1 reduction ≥ 20% survived longer 
than patients with no marker reduction (15  months vs 
9.9  months, p = 0.026 and 14.6  months vs 10  months, 
p = 0.019, respectively) (Fig. 2). Multivariate analysis tak-
ing into account gender, age, prior lines of therapy and 
baseline CEA, CYFRA21-1 and NSE levels showed a bet-
ter prognosis for patients with a higher number of thera-
pies (≥ 2 lines: HR = 0.67, 95% CI 0.48–0.94, p = 0.022) 
and with normal baseline CEA or CYFRA21-1 levels 
(CEA ≤ 5 ng/ml: HR = 0.70, 95% CI 0.49–1.01, p = 0.057; 
CYFRA21-1 ≤ 3.3  ng/ml: HR = 0.68, 95% CI 0.46–1.01, 
p = 0.055). Multivariate analysis taking into account 
CEA and CYFRA21-1 reduction ≥ 20% did not show 
statistically significant results but a tendency towards a 
better prognosis for patients with a CYFRA21-1 reduc-
tion ≥ 20% (HR = 0.55, 95% CI 0.28–1.07, p = 0.079) (data 
not shown). Finally, with regard to histologic subtypes, 
no significant difference in OS was observed between 
patients with adenocarcinoma compared to squamous 
carcinoma (median OS, 9.2 vs 9.8 months). Of note, OS 
was significantly increased only among adenocarcinoma 
patients with CEA reduction ≥ 20% (median OS, 14.8 vs 
9.9 months, p = 0.054) (data not shown).
Discussion
Immune checkpoint inhibitors such as anti-PD1 and anti 
PD-L1, are a recent option of treatment widely used for 
advanced cancers, including NSCLC. However, a sub-
stantial proportion of patients do not respond to these 
agents and display severe toxicities that lead to discon-
tinuation of treatment [27]. On the other hand, in a small 
proportion of patients who do response, immunotherapy 
appears capable of producing long-term responses with 
substantial survival benefits [28]. For these reasons the 
discovery of biomarkers able to predict efficacy would 
be useful to select patients who might benefit from this 
therapy. Recently, particularly in melanoma cancer, sev-
eral studies have investigated the association between 
routinely available peripheral blood biomarkers and 
response to immunotherapy [29–35]. Baseline or post-
treatment changes in absolute leucocytes count (ALC), 







CEA reduction ≥ 20%
No 23 (88.5) 13 (56.5) 0.021
Yes 3 (11.5) 10 (43.5)
CYFRA21-1 reduction ≥ 20%
No 24 (92.3) 9 (37.5) < 0.001
Yes 2 (7.7) 15 (62.5)
NSE reduction ≥ 20%
No 17 (73.9) 11 (52.4) 0.21
Yes 6 (26.1) 10 (47.6)
Table 4 Ability of  CEA and  CYFRA 21-1 to  predict DCR 
(CR + PR + SD) in a multivariate analysis





 ≤ 70 1.0 0.48
 > 70 1.31 (0.6–2.8)
CEA reduction ≥ 20%
No 1.0 0.32
Yes 1.58 (0.6–3.9)
CYFRA 21-1 reduction ≥ 20%
No 1.0 0.002
Yes 4.36 (1.7–11.3)
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leucocytes sub-type counts, serum lactate dehydroge-
nase (LDH) and CRP levels, are among the most prom-
ising aim able to predict tumor response and survival 
in advanced melanoma patients treated with anti-PD-1 
[30, 31] or anti-CTLA4 therapy [32–35]. Conversely, in 
advanced NSCLC, a few blood markers have been pro-
posed as prognostic biomarkers for nivolumab therapy. 
In particular, higher baseline neutrophil to lymphocytes 
ratio (NLR) and platelet to lymphocyte ratio (PLR) have 
shown significant association with worse survival out-
comes [36]. In addition, a recent study has examined a 
panel of six blood biomarkers showing as a combination 
of high ALC, high absolute eosinophil count (AEC) and 
low absolute neutrophil count (ANC) was associated 
with better survival outcome in NSCLC patients treated 
with nivolumab [37]. The role of CEA and CYFRA21-1 
in monitoring tumor response during a first-line chemo-
therapy has been previously demonstrated in a publica-
tion from our Institution [8] and in a recent meta-analysis 
[38], but their role as predictive or treatment monitor-
ing markers with immunotherapy has not yet been elu-
cidated. To the best of our knowledge, this is the first 
study focusing on the role of CEA, CYFRA21-1 and NSE 
as potential markers for tumor response in advanced 
Fig. 1 Progression-free survival according to CEA, CYFRA21-1 and NSE reduction ≥ 20%
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NSCLC patients treated with nivolumab. Interestingly, 
after 4 cycles of nivolumab, we observed that a CEA or 
CYFRA21-1 reduction ≥ 20% over the baseline was sig-
nificantly associated with a better response (at least a dis-
ease control) whereas high baseline markers serum levels 
did not correlate with response to nivolumab. Multivari-
ate analysis confirmed the positive association between 
CYFRA21-1 reduction and DCR. In addition previous 
studies in advanced NSCLC patients had showed that 
changes in CEA or CYFRA21-1 levels during chemo-
therapy [8, 38], radiochemotherapy [39] or targeted ther-
apy [15, 16], had a higher predictive value than baseline 
level alone, indicating the usefulness of both markers for 
treatment monitoring. In agreement with these stud-
ies, we observed a reduction of the tumor markers > 20% 
already at the beginning of the therapy, in particular after 
the first two cycles, suggesting a possible role as mark-
ers able of monitoring the tumor response in an initial 
phase of the treatment also with immunotherapy. We 
also observed a good concordance between histological 
types and tumor markers. In adenocarcinoma and squa-
mous cell carcinoma a CEA and a CYFRA21-1 reduc-
tion ≥ 20%, respectively, were significantly associated 
with a tumor response to nivolumab. In our study high 
baseline values of CEA and CYFRA21-1 were associated 
with worse OS, and, only for CEA, also with worse PFS. 
In this regard, data in literature are rather controversial. 
A recent study [40] reported as a pretreatment serum 
CYFRA21-1 level ≥ 2.2  ng/ml was an independent pre-
dictor of a favorable PFS (median PFS 155 vs 51.5 days, 
p = 0.05), while according to other authors [41] a baseline 
serum CEA level ≥ 5  ng/ml was associated with worse 
PFS. In our study multivariate analysis showed that nor-
mal baseline CEA or CYFRA21-1 levels and a more than 
2 prior lines of therapies were independent prognostic 
factors in patients treated with nivolumab. These results 
suggest that NSCLC patients with normal pretreatment 
CEA or CYFRA21-1 test show a better OS. In addition, 
we observed a significant correlation between mark-
ers reduction after 4 cycles of nivolumab and survival 
outcome. In particular, a CEA or CYFRA21-1 reduc-
tion ≥ 20% was significantly associated with better PFS 
and OS. Specifically, in the multivariate analysis the 
CYFRA21-1 reduction ≥ 20% contributed significantly to 
the prediction of PFS and had a significant trend towards 
a positive prognostic factor. Interestingly, in patients 
with adenocarcinoma we observed a positive associa-
tion between CEA or CYFRA21-1 reduction ≥ 20% and 
longer PFS whereas in patients with lung squamous car-
cinoma a CYFRA21-1 reduction ≥ 20% was statistically 
Table 5 OS according to  clinicophathological 
characteristics
a Median survival not reached





≤ 70 6.1 (0.3–11.8) 0.27
> 70 10.0 (7.2–12.8)
Gender
Male 8.9 (5.1–12.8) 0.76
Female 9.2 (2.3–16.1)
Histology
Adenocarcinoma 9.2 (4.6–13.9) 0.56
Squamous 9.8 (2.5–17.2)
PS ECOG
0 9.2 (5.6–12.8) 0.65
> 1 2.0 (0.1–5.4)
Smoke
Never smoker 9.9 (0.1–20.5) 0.80
Smoker 8.9 (4.7–13.2)
Prior treatment lines, n
1 6.1 (3.6–8.5) 0.036
≥ 2 12.2 (8.2–13.3)
RECIST response
No response 6.4 (4.8–8.0) < 0.001
Response 13.5 (11.2–15.7)
Table 6 OS according to  baseline serum levels and  CEA, 
CYFRA and NSE reduction ≥ 20%
a Median survival not reached




< 5 12.2 (8.1–16.0) 0.035
≥ 5 5.6 (2.9–8.2)
Baseline CYFRA21-1
< 3.3 13.2 (11.0–14.3) 0.005
≥ 3.3 5.6 (3.4–7.7)
Baseline NSE
< 13.4 10.0 (6.2–13.7) 0.028
≥ 13.4 2.2 (0.2–5.0)
CEA reduction ≥ 20%a
No 9.9 (8.5–11.3) 0.026
Yes 15.0 (12.7–17.3)
CYFRA21-1 reduction ≥ 20%a
No 10.0 (8.4–11.6) 0.019
Yes 14.6 (12.4–16.8)
NSE reduction ≥ 20%a
No 11.6 (9.9–13.4) 0.950
Yes 12.4 (9.8–15.0)
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associated with better PFS. In both the histotypes similar 
median OS was observed whereas longer median OS was 
observed only for adenocarcinoma patients with a CEA 
reduction ≥ 20%. Therefore, CEA and CYFRA21-1 seem 
to have a better performance when monitoring adenocar-
cinoma patients, whereas the low number of squamous 
carcinoma patients did not allow to draw a conclusion in 
this sense. These results confirm the association of CEA 
with adenocarcinoma and of CYFRA21-1 with squamous 
carcinoma reported in previous studies [42, 43]. We are 
aware of the limitation of our study. This was a mono-
centric study in which all consecutive patients were 
treated with nivolumab in an expanded access program. 
However, since to include the patients in this program 
the physicians were obligated to follow some inclusion 
and exclusion criteria, that have not allowed to treat all 
the patients with nivolumab, the risk of a patient selec-
tion bias cannot be excluded. Indeed, our study included 
a relatively homogeneous population with the majority 
of the patients stage IV, male and smokers. A strength of 
our study, is the mono-institutional approach that ensure 
that all the clinical and instrumental assessments and 
survival data (DCR, PFS and OS) as well as the labora-
tory analysis were performed consistently among all the 
patients before and during the treatment and data were 
not missed. The reduced number of patients and events 
in our study did not allow to draw definitive conclusions 
and for this reason further investigations are warranted. 
However, the correlation of the CEA and CYFRA21-1 
reduction ≥ 20% with DCR and longer PFS was highly 
significant. If validated, these findings may be use-
ful to physicians to make clinical decision; for example, 
nivolumab treatment may be stopped in patient without 
an evidence of a radiologic response and without CEA 
or CYFRA21-1 reduction ≥ 20% at this time-point, given 
their poor survival outcome and their extremely low 
probability of achieving a controlled disease. In conclu-
sion, CEA and CYFRA21-1 may serve as realible mark-
ers of efficacy in NSCLC patients treated with nivolumab, 
either when considering the determination of the mark-
ers at baseline, or a markers reduction ≥ 20% after 4 
cycles of nivolumab. On the contrary, the reduction of 
NSE was not significant for monitoring the efficacy of 
nivolumab. Further studies in a large population need to 
be conducted to confirm these results that may predict 
response and survival to immunotherapy.
Conclusion
In summary, in advanced NSCLC patients we investi-
gated the utility of analyzed three available serum tumor 
markers in predict tumor response and survival during 
the treatment with nivolumab. This is the first study that 
has analyzed the correlation between CEA, CYFRA21-1 
and NSE reduction over the baseline and the tumor 
response. We found that a CEA or CYFRA21-1 reduc-
tion ≥ 20% after 4 cycles of nivolumab may serve as a reli-
able early marker of efficacy significantly associated with 
better DCR and PFS. Monitoring the changes in CEA or 
CYFRA21-1 during the treatment with nivolumab may 
be of great interest for the prediction of tumor response 
and survival.
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